Literature DB >> 27576328

Subset-specific alterations in frequencies and functional signatures of γδ T cells in systemic sclerosis patients.

Ana Henriques1,2, Cláudia Silva1,3, Mariana Santiago1,4, Maria João Henriques1,4, António Martinho2, Hélder Trindade2, José António Pereira da Silva1,4, Bruno Silva-Santos5, Artur Paiva6,7.   

Abstract

OBJECTIVE AND
DESIGN: Here, we evaluated the distribution and functional profile of circulating CD27+ and CD27- γδ T-cell subsets in systemic sclerosis (SSc) patients to assess their potential role in this disorder.
MATERIALS AND METHODS: Peripheral blood from 39 SSc patients and 20 healthy individuals was used in this study. The TCR-γδ repertoire, cytokine production and cytotoxic signatures of circulating γδ T-cell subsets were assessed by flow cytometry. Gene expression of EOMES, NKG2D and GZMA was evaluated by quantitative RT-PCR in both purified γδ T-cell subsets.
RESULTS: Absolute numbers of γδ T-cell subsets were significantly decreased in SSc groups, likely reflecting their mobilization to the inflamed skin. Both γδ T-cell subsets preserved their relative proportions and Th1-type cytokine responses. However, cytotoxic properties showed significant disease-associated and subset-specific changes. SSc patients exhibited increased percentages of CD27+ γδ T cells expressing granzyme B or perforin and upregulated GZMA expression in diffuse cutaneous SSc. Conversely, EOMES and NKG2D were downregulated in both SSc γδ T-cell subsets vs. normal controls. Interestingly, patients with pulmonary fibrosis showed a biased TCR repertoire, with a selected expansion of effector Vγ9+ γδ T cells associated with increased frequency of cells expressing granzyme B, but decreased IFN-γ production.
CONCLUSIONS: Significant alterations on circulating γδ T-cell subsets suggest a deregulated (increased) cytotoxic activity and thus enhanced pathogenic potential of CD27+ γδ T cells in SSc.

Entities:  

Keywords:  CD27; Cytotoxicity; Gamma–delta T cells; Systemic sclerosis; Th1-type cytokine

Mesh:

Substances:

Year:  2016        PMID: 27576328     DOI: 10.1007/s00011-016-0982-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  29 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

2.  Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.

Authors:  David E Oppenheim; Scott J Roberts; Sarah L Clarke; Renata Filler; Julie M Lewis; Robert E Tigelaar; Michael Girardi; Adrian C Hayday
Journal:  Nat Immunol       Date:  2005-08-14       Impact factor: 25.606

3.  Cutting edge: adaptive versus innate receptor signals selectively control the pool sizes of murine IFN-γ- or IL-17-producing γδ T cells upon infection.

Authors:  Miguel Chaves-Ferreira; Francisco d'Orey; Julie C Ribot; Mélanie Wencker; Natacha Gonçalves-Sousa; Jérémie Decalf; João P Simas; Adrian C Hayday; Bruno Silva-Santos
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis.

Authors:  Patrizia Fuschiotti; Adriana T Larregina; Johnan Ho; Carol Feghali-Bostwick; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2013-01

6.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

7.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.

Authors:  Rajesh R Rao; Qingsheng Li; Kunle Odunsi; Protul A Shrikant
Journal:  Immunity       Date:  2010-01-07       Impact factor: 31.745

8.  The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5'-diphosphate-ribose) polymerase-1.

Authors:  Pengcheng Zhu; Denis Martinvalet; Dipanjan Chowdhury; Dong Zhang; Ann Schlesinger; Judy Lieberman
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

9.  Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites.

Authors:  Francesco Dieli; Fabrizio Poccia; Martin Lipp; Guido Sireci; Nadia Caccamo; Caterina Di Sano; Alfredo Salerno
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  9 in total

1.  Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication.

Authors:  Michael Gernert; Hans-Peter Tony; Eva Christina Schwaneck; Ottar Gadeholt; Matthias Fröhlich; Jan Portegys; Patrick-Pascal Strunz; Marc Schmalzing
Journal:  Rheumatol Int       Date:  2021-10-25       Impact factor: 3.580

2.  Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate.

Authors:  Helena Migalovich Sheikhet; Jose Villacorta Hidalgo; Paul Fisch; Alexandra Balbir-Gurman; Yolanda Braun-Moscovici; Ilan Bank
Journal:  Front Immunol       Date:  2018-04-13       Impact factor: 7.561

Review 3.  Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights.

Authors:  Bingying Dai; Liqing Ding; Lijuan Zhao; Honglin Zhu; Hui Luo
Journal:  Front Pharmacol       Date:  2022-02-03       Impact factor: 5.810

Review 4.  T Cells in Fibrosis and Fibrotic Diseases.

Authors:  Mengjuan Zhang; Song Zhang
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

5.  Integration of Genome-Wide DNA Methylation and Transcription Uncovered Aberrant Methylation-Regulated Genes and Pathways in the Peripheral Blood Mononuclear Cells of Systemic Sclerosis.

Authors:  Honglin Zhu; Chengsong Zhu; Wentao Mi; Tao Chen; Hongjun Zhao; Xiaoxia Zuo; Hui Luo; Quan-Zhen Li
Journal:  Int J Rheumatol       Date:  2018-09-02

Review 6.  Perforins Expression by Cutaneous Gamma Delta T Cells.

Authors:  Katelyn O'Neill; Irena Pastar; Marjana Tomic-Canic; Natasa Strbo
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

7.  Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release.

Authors:  Audrey Benyamine; Jérémy Magalon; Florence Sabatier; Luc Lyonnet; Stéphane Robert; Chloé Dumoulin; Sophie Morange; Karin Mazodier; Gilles Kaplanski; Martine Reynaud-Gaubert; Pascal Rossi; Françoise Dignat-George; Brigitte Granel; Pascale Paul
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

Review 8.  The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases.

Authors:  Ilan Bank
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

9.  Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature.

Authors:  Sónia Fonseca; Vanessa Pereira; Catarina Lau; Maria Dos Anjos Teixeira; Marika Bini-Antunes; Margarida Lima
Journal:  Cells       Date:  2020-03-16       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.